
Roche’s Genentech to acquire inflammatory drug discovery firm Jecure
pharmafile | November 28, 2018 | News story | Research and Development, Sales and Marketing | Genentech, Jecure, Roche, liver disease, nash, pharma
Roche’s subsidiary Genentech has finalised a definitive agreement to acquire Jecure, a US-based biotech which focuses on the discovery of drugs to treat serious inflammatory conditions, in a bid to square up to rivals in the treatment of fatty liver disease.
As part of the deal, Genetech will gain access to the entirety of Jecure’s preclinical portfolio of NLRP3 inhibitors, known by their full name as nucleotide-binding oligomerisation (NOD)-like receptor family Pyrin domain containing protein 3 inhibitors.
It is thought that Roche has made the move to develop therapies for conditions such as non-alcoholic steatohepatitis (NASH), inflammatory bowel disease and liver fibrosis, and muscle in on a share of the market with Pfizer, Novartis and Gilead.
“Genentech has an extensive history of translating pioneering science into transformative medicines. The acquisition of Jecure provides a unique opportunity to bring novel NLRP3 inhibitors to patients,” commented Dr Jeffrey A Stafford, President and CEO of Jecure.
Dr James Sabry, Roche’s Global Head of Pharma Partnering, also added: “We’ve had a long-standing interest in targeting inflammatory pathways that may play a role in a number of serious diseases. We’re excited to combine Jecure’s portfolio with our discovery and development capabilities, as well as our expertise in NLRP3 biology, to potentially help people with inflammatory diseases.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Cell therapy partnership aims to bring liver disease treatment closer to US patients
Resolution Therapeutics has partnered with the Blood Centers of America (BCA) to support community-based delivery …






